Recent Finacing
Recent Raise
Indapta Therapeutics develops off-the-shelf, FcεRIγ-deficient allogeneic g-NK cell therapies with enhanced ADCC for blood cancers, solid tumors and autoimmune diseases, advancing IND-directed Phase 1 trials and partnered manufacturing.
